Testimony before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Liraglutide for Weight Loss

View the presentation as a PDF.

View the Press Release.

Public Citizen strongly opposes the approval of liraglutide (Saxenda) for weight loss because the drug, currently approved for type 2 diabetes, has already been shown to be toxic at a lower dose than that which is being considered for weight loss, while conferring only marginal benefits on weight reduction and no proven long-term health benefits.